Researchers assess the use of nomograms to predict obstructive coronary artery disease

In a new publication from Cardiovascular Innovations and Applications, Zesen Han, Lihong Lai, Zhaokun Pu and Lan Yang from The People's Hospital of Hua County, Henan, China and Henan University of Science and Technology, Henan, China consider the use of nomograms to predict patients with obstructive coronary artery disease.

The authors developed and validated clinical prediction models for the development of a nomogram to estimate the probability of patients having coronary artery disease (CAD).

An individualized clinical prediction model for patients with CAD allowed an accurate estimation in Chinese populations. The Akaike information criterion is a better method in screening risk factors. The net reclassification improvement and integrated discrimination improvement are better than the area under the receiver operating characteristic curve in discrimination. Decision curve analysis can be used to evaluate the efficiency of clinical prediction models.

Source:
Journal reference:

Lai, L., et al. (2021) A Nomogram to Predict Patients with Obstructive Coronary Artery Disease: Development and Validation. Cardiovascular Innovations and Applications. doi.org/10.15212/CVIA.2021.0001.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Medicare coverage for obesity drug raises questions